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Abstract 
Background: The central melanocortin system is broadly involved in the regulation of mammalian nutrient utiliza‑
tion. However, the function of melanocortin receptors (MCRs) expressed directly in peripheral metabolic tissues is still 
unclear. The objective of this study was to investigate the lipolytic capacity of MC1‑5R in differentiated adipocytes 
versus intact white adipose tissue.
Results: Non‑selective MCR agonist α‑MSH, MC5R‑selective agonist PG‑901 and MC4R‑selective agonist LY2112688 
significantly stimulated lipolysis in intact white adipose tissue, whereas stimulation of MCRs in differentiated adi‑
pocytes failed to do so. The lipolytic response of MC5R was decreased in intact human white adipose tissue when 
co‑treating with β‑adrenergic antagonist propranolol, suggesting that the effect may be dependent on neuronal 
innervation via noradrenalin release.
Conclusion: When developing an anti‑obesity therapeutic drug with selective MC4R/MC5R properties, effects on 
lipolysis in white adipose tissue may be physiologically relevant.
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Background
The melanocortin receptors (MCRs) are G-protein cou-
pled receptors (family A), which are stimulated by endog-
enous proopiomelanocortin (POMC) derived agonists 
including ACTH and α-, β- and γ-MSH. The receptor 
system also contains melanocortin receptor-associated 
protein (MRAP) and MRAP2, as well as two antagonists, 
agouti-related peptide (AgRP) and agouti/agouti signal-
ing protein (ASIP).
The melanocortin system has an essential function in 
the regulation of satiety, glucose homeostasis and energy 
expenditure [1, 2]. These effects are mainly mediated by 
MC4R expressed in the hypothalamus and the brain-
stem [3]. MC4R knockout mice have an increased lean 
body mass and fat mass, hyperphagia and disturbances in 
the metabolic response to overnutrition [3, 4]. Likewise, 
humans with MC4R mutations develop obesity [5], and 
in severe, early onset childhood obesity, the frequency of 
mutations in the MC4R locus causing decreased func-
tionality is 4–6  % [6]. It has been shown that MC4R 
mRNA is expressed in autonomic control regions pro-
jecting to postganglionic neurons innervating peripheral 
metabolic tissues [3, 7–10]. Through sympathetic nerve 
innervation, CNS-MC4R has been shown to increase 
lipolysis in WAT [11, 12], insulin sensitivity in muscle 
[12, 13], thermogenesis in brown adipose tissue [10], fatty 
acid oxidation in liver [14] and decrease insulin release in 
pancreatic β-cells [15].
It is still rather unclear as to what extent peripher-
ally expressed MCRs regulate metabolism. Notably, 
melanocortin peptides such as ACTH, β-lipotrophin, 
β-endorphin and α-MSH are released from the pituitary 
gland to the blood stream [16–19], raising the possibil-
ity that there may be peripheral actions of melanocortins 
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on metabolic systems. In addition, POMC expression 
has been identified in peripheral tissues such as the skin, 
testes, ovaries, placenta, adrenal glands, gastrointestinal 
tract, immune cells and tumors [20, 21]. The periph-
eral melanocortin system was initially examined for its 
effects on pigmentation and adrenal function mediated 
by MC1R and MC2R. MC1R action is primarily linked to 
melanocytes where α-MSH stimulation induces synthe-
sis of the brown/black pigment eumelanin [22]. MC2R 
is expressed within the adrenal cortex where it regulates 
glucocorticoid production when activated by ACTH [23] 
and plays a pivotal role in the regulation of the hypotha-
lamic–pituitary–adrenal axis. More recently, α-MSH 
has been shown to inhibit proliferation and adipogen-
esis in human preadipocytes mediated by MC1R, which 
is antagonized by agouti/ASIP [24]. Agouti/ASIP is a 
high affinity antagonist on MC1R and increased ectopic 
expression of this protein is associated phenotypically 
with yellow fur (mice), late onset obesity, hyperphagia, 
increased growth and non-insulin dependent diabetes 
[24]. Notably, ASIP mRNA is increased in subcutaneous 
WAT from type II diabetic patients and is suggested to be 
a paracrine hormone that may induce proliferation and 
adipogenesis [25]. MC1R mRNA expression is shown to 
be co-localized with macrophages in adipose tissue of 
obese subjects, suggesting an inflammatory function of 
this receptor [26]. Furthermore, α-MSH has been shown 
to decrease the expression and release of leptin from adi-
pocytes as a part of a negative feedback loop to the CNS, 
which is antagonized by AgRP [27]. In rats, this effect 
is likely mediated by MC4R and MC5R [28]. Further-
more, a novel study by Panaro et al. shows that MC4R is 
expressed in cells of the gastrointestinal system and that 
MC4R agonist administration elevates plasma PYY and 
GLP-1 in mice [29].
MC5R is extensively distributed in the periphery [30, 
31], and is reported to regulate sebaceous gland secre-
tion [32] and fatty acid oxidation in skeletal muscle [33]. 
The melanocortin system has a well-established lipo-
lytic effect in rodent adipose tissues [34–37]. Studies in 
murine primary adipocytes and differentiated 3T3-L1 
adipocytes show a direct lipolytic effect of MC2R and 
MC5R when stimulated by various endogenous and 
synthetic melanocortin agonists [35, 37, 38]. Moreover, 
an early study by Richter et al. showed a direct effect of 
α-MSH and ACTH on lipolysis in rabbit adipocytes [39]. 
However, it is unclear whether melanocortins have these 
actions in human adipose tissue. Expression of MC1R, 
MC4R and MC5R has been suggested in the adipose tis-
sue of human obese subjects and these receptors may 
reflect an aspect of the pathophysiology of human obesity 
[26, 40, 41].
This study was undertaken to determine the lipol-
ytic capacity of melanocortin receptors in differentiated 
human adipocytes versus intact adipose tissue. Initially, 
binding studies of selective- and non-selective MCR 
compounds were conducted on MC1-5R. We examined 
the possibility that MCR-mediated lipolysis is depend-




α-MSH (Bachem), ACTH (Bachem), PG-901, LY2112688 
(prepared in-house using standard peptide synthesis pro-
tocol); isoproterenol and propranolol were purchased 
from Sigma (Sigma-Aldrich Co. LLC).
Materials
Qiagen RNeasy mini kit was used for extraction of RNA 
from adipocytes. cDNA was synthesized using iScript™ 
(Biorad). Gene expression assays (ABI Life Technology) 
were used in PCR. PrimePCR DNA contamination assay 
from Biorad was used to determine genomic contami-
nation of cDNA. Human subcutaneous adipocytes were 
purchased from Zenbio Inc. 199/EBSS Hyclone medium 
(Thermo Scientific) was used in incubation of human adi-
pose tissue explants. NEFA-HR (2) kit from Wako and 
Glycerol colorimetric assay kit from CaymanChemicals 
was employed when measuring lipolysis.
Preparation of human WAT explants
Adipose tissue biopsies used for stimulation of lipolysis 
were taken from the subcutaneous abdominal region by 
needle aspiration as previously described [42]. The exper-
imental group consisted of 6 non-diabetic females with a 
normal/preobese BMI (average BMI = 25.5). All biopsies 
were transported in sterile containers to the laboratory 
within 30  min after removal. The biopsies were washed 
repeatedly with isotonic saline and were used for subse-
quent culture.
Ethical consideration
Experiments with stimulation of human white adi-
pose tissue explants at Aarhus University Hospital were 
approved by the local Ethics Committee, and the subjects 
provided written informed consent.
RNA extraction and cDNA synthesis
Qiagen RNeasy mini kit was used for extraction of RNA 
from adipocytes purchased at ZenBio. DNAse treat-
ment was used in RNA extraction from adipocytes. The 
RNA was quantified measuring absorbance at 260 nm by 
Nanodrop and the purity of the RNA was indicated by a 
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260/280 ratio of 1.8 or higher to ensure no protein con-
tamination. Finally, the integrity of the RNA was checked 
by visual inspection of the two ribosomal RNAs 18S and 
28S on an agarose gel. iScript™ cDNA synthesis reactions 
were incubated 5 min at 25 °C, 30 min at 42 °C and 5 min 
at 85 °C. We found no genomic contamination of cDNA 
(using Biorad DNA contamination assay).
PCR
In standard PCR, RNA was extracted from adipocytes 
isolated from 3 obese males (purchased from Zenbio) 
and pooled (cDNA 1:10 from 1 μg RNA, 45 cycles). Each 
reaction was prepared using 13  μl of Platinum PCR 
supermix (Invitrogen), 5  μl of gene expression assay 
and 2  μl of cDNA. The gene expression assays used 
were: hsMC1R (NM_002386.3): Hs00267168-S1; 
hsMC2R (NM_000529.2): Hs003000820-S1; hsMC3R 
(NM_019888.3): Hs01562847-S1; hsMC4R (NM_005912.2): 
Hs00271877_S1; hsMC5R (NM_005913.1): Hs00271882_
S1; hsGAPDH (NM_002046.4): Hs02758991_g1.
Binding studies
The human MC1R, MC3R, MC4R and MC5R were 
cloned by PCR and subcloned into the pcDNA3 expres-
sion vector, as previously described by Conde-Frieboes 
et  al. [43]. Cells stably expressing the human MCRs 
were generated by transfecting the expression vector 
into BHK570 cells (ATTC) and using 1 mg/mL G418 to 
select for stable clones. The stable cell lines were cultured 
in DMEM with glutamax, 10 % FCS, 1 % pen/strep, and 
1 mg/mL G418 at 37  °C and 5 % CO2. Binding affinities 
were obtained in  vitro using 125I-NDP-α-MSH binding 
to membranes from recombinant BHK570 cells express-
ing the relevant human melanocortin receptor. Test 
compounds were dissolved to a 4  mM concentration in 
DMSO and diluted in a receptor specific binding buffer. 
A fixed concentration of 125I-NDP-α-MSH and varying 
concentrations (10  μM–1  pM) of non-labelled compet-
ing test compound were added to the cells. A filtration 
system was employed to separate bound from unbound 
radioligand.
NEFA and glycerol release in differentiated human 
adipocytes and WAT explants
Induction of NEFA and glycerol release in adipocytes 
and intact adipose tissue explants was used as a meas-
ure of lipolysis with β-adrenergic agonist isoproterenol 
as a positive control as previously described [35]. When 
using propranolol, 10 μM was used as final concentra-
tion. 250  mg of human adipose tissue was placed in 
15  mL tubes, immediately covered with 2.5  mL of pre-
heated (37 °C) hyclone media and preincubated for 24 h. 
After 24 h, the media was replenished and explants were 
stimulated with the indicated melanocortin peptide for 
3  h before harvesting the supernatant for NEFA and 
glycerol analysis. In house testing has shown no indi-
cations of hypoxia when stimulating explants (data not 
shown). All test compounds were dissolved to 4 mM in 
DMSO (highest DMSO concentration of 0.25  % in the 
assay) and diluted in DPBS buffer +  2  % bovine serum 
albumin (BSA). Human subcutaneous adipocytes pur-
chased from Zenbio Inc., were used in stimulation of 
lipolysis (n  =  4). These adipocytes have been isolated 
from obese males. When receiving the cells (and par-
tially during transportation), the cells was differentiated 
from a pre-state to a mature state before the cells are 
used for experiments. The cells were handled according 
to the description from ZenBio Inc. Two hours was cho-
sen as the optimal incubation time span for primary adi-
pocytes, based on similar experiments in other species 
[35]. The release of NEFA proved to be a reproducible 
measure of lipolysis, though potential re-esterification of 
NEFAs would underestimate the degree of MCR medi-
ated lipolysis. Indeed, a potent release of NEFA was 
stimulated by positive control isoproterenol in both adi-
pocytes and intact adipose tissue explants. Measures of 
melanocortin-stimulated glycerol release were added in 
explant lipolysis studies.
Data analysis and statistics
Data from the NEFA and the glycerol assay were 
obtained using the protocol supplied by the manu-
factures. Released NEFAs were analyzed in Graphpad 
Prism and one-tailed t test was used to calculate statisti-
cal significance between 2 groups (*p < 0.05, **p < 0.01, 
***p  <  0.001, no * indicates insignificance). Ki values in 
bindings studies were calculated as Ki = IC50/1 + [radio-
ligand]/Kd. Data from binding studies was analyzed in 
Graphpad Prism.
Results
Binding data of known melanocortin analogues to MC1R, 
MC3R, MC4R and MC5R
In order to assess MCR agonist specificity, competi-
tion binding curves of α-MSH, ACTH, PG-901 and 
LY2112688 were obtained using cells overexpress-
ing the human MCRs (Table  1). MC2R is acknowl-
edged to be activated only by ACTH [23], and for 
this reason, binding studies were not performed on 
this receptor. Our binding data support that remain-
ing MCRs bind ACTH with relatively high affinities 
(MC1R > MC4R > MC3R > MC5R), which is also con-
sistent with previous studies [44]. Results obtained 
support present literature on human MCRs, stating 
that α-MSH is a non-selective agonist that binds to all 
MCRs [45]. LY2112688 has previously been studied 
Page 4 of 9Møller et al. BMC Res Notes  (2015) 8:559 
by Greenfield et  al., who found that the agonist was 
highly selective for MC4R, having an increased affin-
ity for MC4R over MC1R of a factor more than 30 and 
over MC3R of a factor of more than 100 [46]. We sup-
port that LY2112688 is selective for human MC4R 
(Ki =  0.13 ±  0.01), but we find the binding rank order 
to be MC4R  >  MC3R  >  MC1R. Notably, the affinity of 
LY2112688 for MC1R is 165 ±  51  nM, which is in the 
range of concentrations used in lipolysis assay. In the lit-
erature, PG-901 binds MC5R (agonist), as well as MC3R 
and MC4R (antagonist) with high affinity [47], which is 
consistent with our studies.
NEFA release in subcutaneous explants from human white 
adipose tissue
To examine the function of MCRs in human adipose 
tissue, we investigated the ability of MCR agonists to 
stimulate lipolysis in intact explants (Fig.  1). Isoproter-
enol, which is known to stimulate release of NEFA in 
human WAT through activation of the β-adrenergic 
receptors, was used as a positive control. Indeed, the 
release of NEFA was increased by 114 % using 100 nM 
isoproterenol compared to vehicle (Fig.  1a). Fur-
thermore, 100  nM α-MSH, MC4R-selective agonist 
LY2112688 and MC5R-selective agonist PG-901 stimu-
lated a low, though significant, release of NEFA (32, 46 
and 38  % increase compared to the vehicle). PG-901 
and LY2112688 also stimulated release of glycerol. 
Compared to isoproterenol, α-MSH, LY2112688 and 
PG-901 stimulated lipolysis with a relatively lower Emax. 
Notably, ACTH failed to stimulate NEFA and glycerol 
release in human WAT explants (Fig.  1a, b). Binding 
results obtained in this study support that LY2112688 
has high affinity (Ki =  0.13 ±  0.01  nM) for the human 
MC4R and lower affinity for other human melanocortin 
receptors. However, as LY2112688 bind to MC1R with a 
Ki = 165 ± 51 nM, the LY2112688-stimulation of lipoly-
sis may partially be mediated by MC1R considering the 
concentration used.
MCRs have no lipolytic effect in differentiated adipocytes 
from obese human subjects
We investigated the ability of the MCR agonists to stim-
ulate lipolysis in subcutaneous adipocytes from obese 
males (purchased from Zenbio). While isoproterenol 
induced a potent release of NEFA in human subcutane-
ous adipocytes (EC50 = 1.64 ± 0.34 nM) α-MSH, ACTH, 
PG-901 and LY2112688 all failed to stimulate NEFA 
release (Fig.  2). We also stimulated visceral adipocytes 
with the same results as in Fig. 2 (data not shown). Stand-
ard PCR showed that the expression of MC3R and MC4R 
mRNA is low in subcutaneous adipocytes in the condi-
tions used, whereas the expression of MC1R, MC2R and 
MC5R is higher (Fig. 2).
The partial lipolytic effect of MC5R in explants is 
dependent on postsynaptic innervation
Since we only observed a lipolytic effect in intact adi-
pose tissue and not in adipocytes, we examined whether 
MCR-mediated lipolysis involves neuronal interaction. 
Hence, we co-incubated PG-901 and LY2112688 with 
β-adrenergic antagonist propranolol in intact adipose tis-
sue (Fig.  3). Use of propranolol significantly decreased 
the release of NEFA stimulated by isoproterenol and 
MC5R selective agonist PG-901. This result suggests 
that the lipolytic effect of MC5R may be mediated by 
noradrenalin released from postsynaptic nerve fibers 
innervating the adipose tissue. Use of propranolol did not 
significantly decrease the release of NEFA stimulated by 
MC4R-selective agonist LY2112688, although there is a 
clear trend.
Discussion
Melanocortin receptors are important central regulators 
of energy metabolism and feeding behavior. These recep-
tors also have a direct lipolytic effect in rodent [35, 37, 38] 
and rabbit [39] adipose tissues. The storage and release 
of lipids in adipose tissue is a highly regulated process, 
which play an essential role in whole body homeostasis. 
Table 1 Binding (Ki) of melanocortin peptides to human MCRs: Indicated values are an average from repeated independ-
ent experiments (±SEM)
Ki values were calculated from competition binding curves of α-MSH, PG-901 and LY2112688 obtained on cells expressing MC1, 3, 4 and 5R as described using a fixed 
concentration of I125-NDP-α-MSH and increasing amounts of non-labelled competing peptides (1 pM–10 μM)
Test compound hMC1R hMC3R hMC4R hMC5R
Ki (nM) Ki (nM) Ki (nM) Ki (nM)
LY2112688 165 ± 51 (3) 74 ± 27 (3) 0.13 ± 0.01(3) 1713 ± 686 (3)
PG‑901 2700 ± 153 (3) 11 ± 0.5 (4) 0.08 ± 0.01 (3) 1.7 ± 0.6 (4)
α‑MSH 1.5 ± 0.4 (18) 46 ± 5 (9) 10.16 ± 3.4 (3) 150 ± 30 (7)
ACTH 0.09 ± 0.01 (3) 11.1 ± 1.5 (5) 1.2 ± 0.2 (3) 46 ± 9.5 (5)
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A systemic abundance of both endogenous melanocortin 
agonists and antagonists have been established [1, 18, 48] 
and MCRs are expressed in peripheral tissues relevant for 
lipid metabolism. Hoch et  al. established MC1R mRNA 
expression in adipose tissue [26], Chhajlani et al. identi-
fied MC1R and MC5R in omental adipose tissue [41] and 
Chagnon et al. linked MC4R and MC5R with an obese-
related phenotype [40]. The presence of a peripheral mel-
anocortin system in adipose tissue is supported by results 
from this study.
In this study, we show that α-MSH, MC5R selective 
agonist PG-901 and MC4R selective agonist LY2112688 
significantly stimulate release of NEFA in intact adi-
pose tissue. Notably, as LY2112688 bind to MC1R with a 
Ki = 165 ± 51 nM, the LY2112688-stimulation of lipoly-
sis may partially be mediated by MC1R considering the 
concentration used. A recent study by Rodrigeus et  al. 
showed that α-MSH-stimulated MC5R regulates both 
lipolysis and re-esterification in murine 3T3-L1 cells, 
though the global effect is a decrease in adipocyte fat 
mass [49]. This may be relevant in terms of the MC5R-
mediated lipolysis seen is this study, as some of the 
released free fatty acids (FFAs) may be re-esterified and 
taken up by the adipocyte again. However, as PG-901 
and LY2112688 also stimulated release of glycerol 
there seems to be a persistent lipolytic effect of these 
compounds.
The lipolytic response of PG-901 was significantly 
decreased when using β-adrenergic antagonist pro-
pranolol, suggesting that the effect may be dependent on 
neuronal innervation via noradrenalin release (Fig.  4). 
Propranolol is a non-selective β-adrenergic antagonist 
that is used as a golden standard for inhibition of neu-
ronal innervation. However, it should be taken into 
account, that there may be downstream MCR mecha-
nisms of propranolol that are unknown, which is a pre-
caution using this antagonist. Depleting the explants with 
reserpine before stimulation could add additional confi-
dence to the result of propranolol. Centrally expressed 
MC4R in the hypothalamus and the brainstem has in sev-
eral studies been shown to regulate peripheral metabo-
lism through sympathetic nerve innervation. Through 
innervation, CNS-MC4R increases lipolysis in WAT [11, 
12], insulin sensitivity in muscle [12, 13], thermogenesis 
in brown adipose tissue (BAT) [10], fatty acid oxidation 
in liver [14] and decreases insulin release in pancreatic 
β-cells [15] as mentioned previously. Likewise, Wellhöner 
et  al. showed that intranasal MSH/ACTH(4-10) admin-
istration increased glycerol concentrations in WAT, pre-
sumably mediated by centrally expressed MC4R [50]. 
Fig. 1 Non‑esterified fatty acid (NEFA) and glycerol release in intact adipose tissue explants from human. a NEFA release was measured after stimu‑
lation with increasing doses of isoproterenol or the indicated melanocortin peptide (100 nM–10 μM) in subcutaneous explants from non‑obese 
females. The mean of 6 independent experiments (α‑MSH, 3 independent experiments) in triplicate wells (mean ± SEM) are shown. b Glycerol 
release was measured after stimulation with increasing doses of isoproterenol or the indicated melanocortin peptide (100 nM–10 μM) in subcuta‑
neous explants from non‑obese females. The mean of 2 independent experiments in triplicate wells (mean ± SEM) are shown. Unpaired one‑tailed 
t test was used to calculate statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle)
Page 6 of 9Møller et al. BMC Res Notes  (2015) 8:559 
However, the mode of action suggested in the present 
study is not a CNS-MCR regulated pathway. Instead, 
we suggest that peripherally expressed MC5R co-local-
ized with post-synaptic neurons directly in adipose tis-
sue regulate low grade lipolysis. Notably, the central and 
peripheral regulation of MCR-mediated lipolysis may not 
exclude each other. α-MSH has been shown to inhibit 
proliferation and adipogenesis in human preadipocytes 
mediated by MC1R, which is antagonized by agouti [24]. 
Considering the above, a lipolytic capacity of α-MSH in 
human adipose tissue seems plausible. If stimulation of 
MC5R/MC4R in adipose tissue leads to increased lev-
els of plasma FFA and glycerol, these lipids may likely be 
absorbed and metabolized in the liver. This may lead to 
increased hepatic lipid deposition and potentially hepatic 
insulin resistance. However, if energy expenditure simul-
taneously is increased by melanocortins these lipids may 
also serve as energy substrates to be utilized in mus-
cle. Notably, An et  al. has shown that MC5R mediates 
α-MSH-stimulated fatty acid oxidation in muscle tissue 
[33]. Additional studies are needed to determine where 
in fact the released lipids are absorbed and metabolized.
We find no lipolytic capacity of ACTH in either adipo-
cytes or intact human adipose tissue, which is supported 
by other studies [51, 52]. ACTH is a larger peptide than 
both α-MSH and the synthetic melanocortin compounds 
used in this study. It is possible that the lack of lipolytic 
response ex vivo observed when stimulating with ACTH 
is due to the size of the peptide. Opposing results have 
been reported by Xue et al. who stimulated lipolysis using 
ACTH in adipocytes isolated from subcutaneous adipose 
tissue of non-diabetic human [53].
We, and others, have previously shown that the mel-
anocortin system is involved in peripheral regulation of 
adipocyte metabolism in mice and has direct lipolytic 
capacity in addition to central regulation. Indeed, ACTH 
and α-MSH were reported to have a lipolytic capacity in 
primary mouse adipocytes, which is mediated by MC2R 
and MC5R [35, 37, 38]. This result was not found in 
human adipocytes, which suggests essential species dif-
ferences in the melanocortin system between mice and 
humans. The lack of lipolytic response seen in adipocytes 
is supported by previous studies by Hoch et al. [52]. Hoch 
et al. induced a weak cAMP response using NDP-α-MSH 
in mesenchymal stem cell-derived adipocytes. However, 
Fig. 2 Non‑esterified fatty acid (NEFA) release in human subcu‑
taneous adipocytes: a Adipocytes purchased from ZenBio were 
incubated with increasing concentrations (1 pM–10 μM) of positive 
control isoproterenol (EC50 = 1.46 ± 0.34 nM), ACTH, α‑MSH, PG‑901 
and LY2112688 (n = 4). NEFA release was measured as described. 
Experiments were carried out in duplicates. Data are shown as aver‑
age values ± SEM. b MC1‑5R and GAPDH mRNA expression was 
measured in same adipocytes (n = 3 pooled). cDNA was synthesized 
and mRNA levels determined by standard PCR (cDNA 1:10 from 1 μg 
RNA, 45 cycles)
Fig. 3 Non‑esterified fatty acid (NEFA) release in human white adipose tissue (WAT) explants ± propranolol: NEFA was measured after stimulation 
with indicated melanocortin peptide analogue (100 nM–10 μM) in subcutaneous explants from female human ± 10 μM β‑adrenergic antagonist 
propranolol (PRO). The mean ± SEM of 3 independent experiments in triplicate wells are shown. Unpaired one‑tailed t test was used to calculate 
statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle; +p < 0.05, ++p < 0.01, +++p < 0.001 vs. −7)
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they did not find an effect on lipolysis in either these cells 
or in intact adipose tissue explants [52].
Further studies are needed in order to establish the rel-
evance of the melanocortin receptor accessory proteins, 
MRAP and MRAP2, in intact adipose tissue versus adi-
pocytes. Studies have shown that all MCRs may employ 
an accessory protein, which modulates the functional-
ity of the receptor [54]. It may be that MRAP/MRAP2 
mRNA levels are not equally expressed in the stroma vas-
cular fraction (SVF) and in isolated adipocytes.
Collectively, the Emax induced by melanocortin pep-
tides in intact adipose tissue explants is small compared 
to isoproterenol. It is possible that the melanocortin sys-
tem has other functions in adipose tissue than induction 
of lipolysis. The SVF of adipose tissue consists of cells 
such as preadipocytes, mesenchymal stem cells, several 
types of inflammatory cells, as well as nerve fibers and 
blood vessels. α-MSH inhibits TNF-α-induced NF-κB in 
immune cells [55], as well as in a subset of other human 
cells such as melanocytes, fibroblasts, keratinocytes, 
endothelial cells and Schwann cells of the peripheral 
nervous system [56]. Suppression of NF-κB potentially 
controls the expression of 150 genes including cytokines 
for which reason the involvement of the melanocortins 
in inflammation is potentially profound [56]. It has been 
shown that the inflammatory effects of the melanocortin 
system are regulated through mainly MC1R and MC3R 
[26, 56]. Hence the primary function of MCRs in human 
adipose tissue may be inflammatory rather than lipolytic 
[52].
We find that various selective and non-selective mel-
anocortin peptides significantly induce low-grade lipol-
ysis in intact human adipose tissue. The physiological 
relevance of these receptors in terms of human adipose 
tissue lipolysis is probably minimal. The plasma level of 
circulating endogenous α-MSH and ACTH is on average 
reported to be 11  pmol/l (~0.011  nM) and 14.5  pmol/l 
(~0.015 nM) [27]. These concentrations are not compat-
ible with the concentration of endogenous and synthetic 
melanocortin receptor ligands used in this study. How-
ever, even the physiological concentration of endogenous 
α-MSH circulating in the human body is below the EC50 
values for the peripheral MCRs [57]. Does circulating 
α-MSH have any physiological relevance for adipose tis-
sue metabolism? In terms of circulating endogenous mel-
anocortin peptides the answer is probably no. However, 
in terms of developing an anti-obesity therapeutic drug 
with selective MC4R/MC5R properties directed against 
the effects on satiety and energy expenditure, the answer 
may be yes. In addition, paracrine POMC-secretion/
Fig. 4 An overview of melanocortin receptor (MCR)‑mediated lipolysis in intact human white adipose tissue (WAT). It is hypothesised that MC4/5R 
mRNA is expressed on nerve terminals innervating WAT. α‑MSH from the circulation or from ectopic production binds to MC4/5R, which increase 
the release of noradrenalin from the terminal. Stimulated β1–3‑adrenergic receptors couple to Gαs and downstream adenylate cyclase leading to 
increased intracellular cAMP and activation of protein kinase A (PKA). The induction of lipolysis mediated by MC4R and MC5R is suggested to be 
dependent on neuronal innervation via noradrenalin release, since co‑incubation of propranolol (non‑selective β‑adrenergic receptor antagonist) 
inhibits NEFA release
Page 8 of 9Møller et al. BMC Res Notes  (2015) 8:559 
ectopic POMC-production could increase the concen-
tration and exposure of ACTH and α-MSH to MCRs in 
peripheral tissues such as white adipose tissue.
Conclusion
Selective and non-selective melanocortin peptides sig-
nificantly induce low-grade lipolysis in intact human adi-
pose tissue but not in adipocytes. The lipolytic response 
of MC5R was decreased in intact human white adipose 
tissue when co-treating with β-adrenergic antagonist 
propranolol, suggesting that the effect may be dependent 
on neuronal innervation via noradrenalin release. These 
effects may be physiologically relevant, when developing 
an anti-obesity therapeutic drug with selective MC4R/
MC5R properties.
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